Vesting of awards under Long Term Incentive Plan
Source: RNS
Vesting of awards under the Long Term Incentive Plan
Hong Kong, Shanghai & Florham Park, NJ: Friday, April 23, 2021: Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) announces that the non-performance based awards granted under the Long Term Incentive Plan ("LTIP") on April 20, 2020 to the following persons discharging managerial responsibilities were vested on April 20, 2021:-
|
Award Holder |
|
Number of American depositary shares ("ADS") |
|
|
|
|
|
Mr Simon To (Executive Director) |
|
2,3971 |
|
Dr Dan Eldar (Non-executive Director ("NED")) |
|
2,397 |
|
Ms Edith Shih (NED) |
|
2,3972 |
|
Mr Paul Carter (Independent Non-executive Director ("INED")) |
|
2,037 |
|
Dr Karen Ferrante (INED) |
|
2,397 |
|
Mr Graeme Jack (INED) |
|
2,397 |
|
Professor Tony Mok (INED) |
|
2,397 |
Notes:
(1) Similar to the arrangement for his Director's fees, these ADSs were not received by Mr Simon To, but were received by or for the account of his employer, Hutchison Whampoa (China) Limited.
(2) Similar to the arrangement for her Director's fees, these ADSs were not received by Ms Edith Shih, but were received by or for the account of her employer, Hutchison International Limited.
The notifications set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.
(a) Dr Dan Eldar
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Dr Dan Eldar
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Non-Executive Director
|
|
b) |
Initial notification/Amendment
|
Initial notification
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name
|
Hutchison China MediTech Limited |
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035 |
||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
|
N/A |
||||
|
e) |
Date of the transaction |
2021-04-20
|
||||
|
f) |
Place of the transaction |
Outside a trading venue
|
||||
(b) Mr Paul Carter
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Mr Paul Carter
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Independent Non-Executive Director
|
|
b) |
Initial notification/Amendment
|
Initial notification
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name
|
Hutchison China MediTech Limited |
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035 |
||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
|
N/A |
||||
|
e) |
Date of the transaction |
2021-04-20
|
||||
|
f) |
Place of the transaction |
Outside a trading venue
|
||||
(c) Dr Karen Ferrante
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Dr Karen Ferrante
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Independent Non-Executive Director
|
|
b) |
Initial notification/Amendment
|
Initial notification
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name
|
Hutchison China MediTech Limited |
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035 |
||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
|
N/A |
||||
|
e) |
Date of the transaction |
2021-04-20
|
||||
|
f) |
Place of the transaction |
Outside a trading venue
|
||||
(d) Mr Graeme Jack
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Mr Graeme Jack
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Independent Non-Executive Director
|
|
b) |
Initial notification/Amendment
|
Initial notification
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name
|
Hutchison China MediTech Limited |
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035 |
||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
|
N/A |
||||
|
e) |
Date of the transaction |
2021-04-20
|
||||
|
f) |
Place of the transaction |
Outside a trading venue
|
||||
(e) Professor Tony Mok
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|
|
a) |
Name |
Professor Tony Mok
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Independent Non-Executive Director
|
|
b) |
Initial notification/Amendment
|
Initial notification
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
|
a) |
Name
|
Hutchison China MediTech Limited |
|
b)
|
LEI |
2138006X34YDQ6OBYE79 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument, type of instrument
Identification code
|
ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035 |
||||
|
b) |
Nature of the transaction
|
Vesting of awards granted on April 20, 2020 under HUTCHMED's LTIP
|
||||
|
c) |
Price(s) and volume(s) |
|
||||
|
d) |
Aggregated information
|
N/A |
||||
|
e) |
Date of the transaction |
2021-04-20
|
||||
|
f) |
Place of the transaction |
Outside a trading venue
|
||||
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,200 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED's filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
CONTACTS
|
Investor Enquiries |
|
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
|
Annie Cheng, Vice President |
+1 (973) 567 3786 |
|
|
|
|
Media Enquiries |
|
|
Americas - Brad Miles, |
+1 (917) 570 7340 (Mobile) |
|
Europe - Ben Atwell / Alex Shaw, |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) |
|
Asia - Joseph Chi Lo / Zhou Yi, |
+852 9850 5033 (Mobile) / +852 9783 6894 (Mobile) |
|
|
|
|
Nominated Advisor |
|
|
Freddy Crossley / Atholl Tweedie, |
+44 (20) 7886 2500 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
